Pharmacological intervention with 5-lipoxygenase: New insights and novel compounds

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 5, 2005, Pages 505-519

  Werz, Oliver ^a   Steinhilber, Dieter ^b  

^a GOETHE UNIVERSITY   (Germany)

^b NONE

Author keywords

5 lipoxygenase; Arachidonic acid; Asthma; Inflammation; Inhibitor; Leukotriene

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 1 ETHYL 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 2 QUINOLONE; 2 [4 [2 (4 CHLOROPHENYLTHIO)ETHOXY] 5 (3 HYDROXY 3 METHYLUREIDOMETHYL) 3 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 2,3 DIHYDRO 6 [3 (2 HYDROXYMETHYLPHENYL)ALLYL] 5 BENZOFURANOL; 2,3 HYDROXYQUINAZOLIN 4 ONE DERIVATIVE; 2,5 DIARYLTETRAHYDROFURAN DERIVATIVE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 3 O ACETYL 11 KETO BOSWELLIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 ARYLPIPERIDINE DERIVATIVE; 6 (2 CHLOROPHENYL) 9 [(3,4 DIMETHOXYPHENYL)THIOMETHYLTHIOCARBONYL] 4,7,8,10 TETRAHYDRO 1 METHYLPYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; 7 CHLORO 4 HYDROXY 2 (4 METHOXYBENZYL) 3 METHYL 5 PROPYLBENZOFURAN; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ATRELEUTON; BENZHYDRYL DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; BWA 4C; CAFFEIC ACID; CARBOXYLIC ACID DERIVATIVE; CETIRIZINE; CIRSILIOL; CJ 13454; CJ 13610; CMI 206; CMI 977; COMPLEMENTARY DNA; COUMARIN DERIVATIVE; CYSTEINE; DOCEBENONE; EARLY GROWTH RESPONSE FACTOR 1; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXAMIC ACID DERIVATIVE; HYDROXYUREA; HYPERFORIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLE DERIVATIVE; L 697198; LDP 977; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LICOFELONE; LINAZOLAST; LORATADINE; MEPYRAMINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONTELUKAST; N [4 (4 BENZHYDRYL 1 PIPERAZINYL)BUTYL] 3 (6 METHYL 3 PYRIDYL)ACRYLAMIDE; NORDIHYDROGUAIARETIC ACID; PHENIDONE; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN C MYB; RETINOIC ACID RECEPTOR; TETRAHYDROPYRAN DERIVATIVE; THIAZOLE DERIVATIVE; THIAZOLIDINDIONE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR SP3; TRANSFORMING GROWTH FACTOR BETA; UCB 35440; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON; ZM 211965;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; BONE METABOLISM; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CATALYSIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; HUMAN; INFLAMMATORY DISEASE; LEUKOCYTE; MALIGNANT NEOPLASTIC DISEASE; MASTOCYTOSIS; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; ULCERATIVE COLITIS;

EID: 19044395646     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.5.505     Document Type: Review

References (98)

1. SAMUELSSON B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science (1983) 220:568-575.
2. RÅDMARK O: Arachidonate 5-lipoxygenase. J. Lipid Mediat. Cell (1995) 12:171-184.
3. HAMMARBERG T, KUPRIN S, RADMARK O et al.: Epr investigation of the active site of recombinant human 5-lipoxygenase: inhibition by selenide. Biochemistry (2001) 40:6371-6378.
4. CHASTEEN ND, GRADYJK. SKOREY KI et al.: Characterization of the non-heme iron center of human 5-lipoxygenase by electron paramagnetic resonance, fluorescence, and ultraviolet-visible spectroscopy: redox cycling between ferrous and ferric states. Biochemistry (1993) 32:9763-9771.
5. FALGUEYRET JP, DESMARAIS S, ROY PJ et al.: N-(4-chlorophenyl)-N-hydroxy-N′-(3-chlorophenyl)urea, a general reducing agent for 5-, 12-, and 15-lipoxygenases and a substrate for their pseudoperoxidase activities. Biochem. Cell Biol. (1992) 70:228-236
6. SERHAN C: Lipoxins and aspirin-triggered 15-epi-lipoxins. In: Inflammation. Basic Principles and Clinical Correlates. Gallin JL, Syndermann R (Eds), Lipincott Williams & Williams, Philadelphia (1999).
7. BRINK C, DAHLEN SE, DRAZEN J et al.: International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. (2003) 55:195-227.
8. O' FLAHERTY JT, TAYLOR JS, KUROKI M: The coupling of 5-oxo-eicosanoid receptors to heterotrimeric G proteins. J. Immunol. (2000) 164:3345-3352.
9. CLAESSON HE, DAHLEN SE: Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J. Intern. Med. (1999) 245:205-227.
10. 4 augments neutrophil phagocytosis of Klebsiella pneumoniae. Infect. Immun. (2001) 69:2011-2016.
11. MANCUSO P, STANDIFORD TJ, MARSHALL T et al.: 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of Klebsiella pneumoniae. Infect. Immun. (1998) 66:5140-5146.
12. NICOSIA S, CAPRA V, ROVATI GE: Leukotrienes as mediators of asthma. Pulm. Pharmacol. Ther. (2001) 14:3-19.
13. DAHLÉN SE, HEDQVIST P, HAMMARSTRÖM S et al.: Leukotrienes are potent constrictors of human bronchi. Nature (1980) 288:484-486
14. CHEN XS, SHELLER JR, JOHNSON EN et al.: Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature (1994) 372:179-182.
15. RÅDMARK O: 5-lipoxygenase-derived leukotrienes: mediators also of atherosclerotic inflammation. Arterioscler. Thromb. Vasc. Biol. (2003) 23:1140-1142.
16. HELGADOTTIR A, MANOLESCU A, THORLEIFSSON G et al.: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. (2004) 36:233-239.
17. DWYER JH, ALLAYEE H, DWYER KM et al.: Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. (2004) 350:29-37.
18. ROMANO M, CLARIA J: Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB. J. (2003) 17:1986-1995.
19. BONEWALD LF, FLYNN M, QIAO M et al.: Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv. Exp. Med. Biol. (1997) 433:299-302.
20. FUNK CD: The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. BBA Lipid Lipid Metab. (1996) 1304:65-84.
21. SILVERMAN ES, DU J, DE SANCTIS GT et al.: Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am. J. Respir. Cell. Mol. Biol. (1998) 19:316-323.
22. STEINHILBER D, BRUNGS M, WERZ O et al.: The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J. Biol. Chem. (1995) 270:7037-7040.
23. STEINHILBER D: 5-Lipoxygenase: enzyme expression and regulation of activity. Pharm. Acta Helv. (1994) 69:3-14.
24. JANSSEN-TIMMEN U, VICKERS PJ, WITTIG U et al.: Expression of 5-lipoxygenase in differentiating human skin keratinocytes. Proc. Natl. Acad. Sci. USA (1995) 92:6966-6970.
25. SPANBROEK R, STARK HJ, JANSSEN-TIMMEN U et al.: 5-Lipoxygenase expression in Langerhans cells of normal human epidermis. Proc. Natl. Acad. Sci. USA (1998) 95:663-668.
26. LAMMERS C-H, SCHWEITZER P, FACCHINETTI P et al.: Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signalling. J. Neurochem. (1996) 66:147-152.
27. BRUNGS M, RÅDMARK O, SAMUELSSON B et al.: Sequential induction of 5-lipoxygenase gene expression and activity in Mono Mac 6 cells by transforming growth factor-β and 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA (1995) 92:107-111.
28. STEINHILBER D, RÅDMARK O, SAMUELSSON B: Transforming growth factor β upregulates 5-lipoxygenase activity during myeloid cell maturation. Proc. Natl. Acad. Sci. USA (1993) 90:5984-5988.
29. UHL J, KLAN N, ROSE M et al.: The 5-lipoxygenase promoter is regulated by DNA methylation. J. Biol. Chem. (2001) 12:12.
30. KLAN N, SEUTER S, SCHNUR N et al.: Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity. Biol. Chem. (2003) 384:777-785.
31. MANEV H, UZ T: DNA hypomethylating agents 5-aza-2′-deoxycytidine and valproate increase neuronal 5-lipoxygenase mRNA. Eur. J. Pharmacol. (2002) 445:149-50.
32. WERZ O: 5-Lipoxygenase: cellular biology and molecular pharmacology. Curr. Drug Target Inflamm. Allergy (2002) 1:23-44.
33. 4 by human neutrophils. J. Biol. Chem. (1987) 262:15370-15376.
34. 4 by human neutrophils: involvement of protein kinase C activation in regulation of the 5-lipoxygenase pathway. J. Immunol. (1987) 138:3396-3402.
35. POULIOT M, MCDONALD PP, KHAMZINA L et al.: Granulocyte-macrophage colony-stimulating factor enhances 5-lipoxygenase levels in human polymorphonuclear leukocytes. J. Immunol. (1994) 152:851-858.
36. 4 in human neutrophils in response to platelet-activating factor. J. Immunol. (1991) 146:1204-1211.
37. WERZ O, KLEMM J, SAMUELSSON B et al.: Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation of 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood (2001) 97:2487-2495.
38. SURETTE ME, DALLAIRE N, JEAN N et al.: Mechanisms of the priming effect of lipopolysaccharides on the biosynthesis of leukotriene B4 in chemotactic peptide-stimulated human neutrophils. FASEB J. (1998) 12:1521-1531.
39. BINDU PH. SASTRY GM, SASTRY GN: Characterization of calcium and magnesium binding domains of human 5-lipoxygenase. Biochem. Biophys. Res. Commun. (2004) 320:461-467.
40. HEMAK J, GALE D, BROCK TG: Structural characterization of the catalytic domain of the human 5-lipoxygenase enzyme, J. Mol. Model (2002) 8:102-112.
41. ROUZER CA, SAMUELSSON B: The importance of hydroperoxide activation for the detection and assay of mammalian 5-lipoxygenase. FEBS Lett. (1986) 204:293-296.
42. HATZELMANN A, SCHATZ M, ULLRICH V: Involvement of glutathione peroxidase activity in the stimulation of 5-lipoxygenase activity by glutathione-depleting agents in human polymorphonuclear leukocytes. Eur. J. Biochem. (1989) 180:527-533.
43. WEITZEL F, WENDEL A: Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone. J. Biol. Chem. (1993) 268:6288-6292.
44. 2+-dependent resistance of 5-lipoxygenase activity against inhibition by glutathione peroxidase-1. J. Biol. Chem. (2003) 278:42846-42853.
45. STRAIF D, WERZ O, KELLNER R et al.: Glutathione peroxidase-1 but not 4 is involved in the regulation of cellular 5-lipoxygenase activity in monocytic cells. Biochem. J. (2000) 349:455-461
46. AHARONY D, STEIN RL: Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. J. Biol. Chem. (1986) 261:11512-11519.
47. ROUZER CA, SAMUELSSON B: Reversible, calcium-dependent membrane association of human leukocyte 5-lipoxygenase. Proc. Natl. Acad. Sci. USA (1987) 84:7393-7397.
48. 4 synthetase activity. Biochim. Biophys. Acta (1994) 1215:300-306.
49. KULKARNI S, DAS S, FUNK CD et al.: A molecular basis of specific subcellular localization of the C2-like domain of 5-lipoxygenase. J. Biol. Chem. (2002) 277:13167-13174.
50. OCHI K, YOSHIMOTO T, YAMAMOTO S et al.: Arachidonate 5-lipoxygenase of guinea pig peritoneal polymorphonuclear leukocytes. Activation by adenosine 5′-triphosphate. J. Biol. Chem. (1983) 258:5754-5758.
51. ROUZER CA, SAMUELSSON B: On the nature of the 5-lipoxygenase reaction in human leukocytes: enzyme purification and requirement for multiple stimulatory factors. Proc. Natl. Acad. Sci. USA (1985) 82:6040-6044.
52. ROUZER CA, SHIMIZU T, SAMUELSSON B: On the nature of the 5-lipoxygenase reaction in human leukocytes: Characterization of a membrane-associated stimulatory factor. Proc. Natl. Acad. Sci. USA (1985) 82:7505-7509.
53. PROVOST P, SAMUELSSON B, RÅDMARK O: Interaction of 5-lipoxygenase with cellular proteins. Proc. Natl. Acad. Sci. USA (1999) 96:1881-1885.
54. WERZ O, KLEMM J, SAMUELSSON B et al.: 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc. Natl. Acad. Sci. USA (2000) 97:5261-5266.
55. WERZ O. BURKERT E, FISCHER L et al.: Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. FASEB J. (2002) 16:1441-1443.
56. WERZ O, SZELLAS D, STEINHILBER D, RÅDMARK O: Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPKAP kinase-2. J. Biol. Chem. (2002) 277:14793-14800.
57. WERZ O, BURKERT E, SAMUELSSON B et al.: Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood (2002) 99:1044-1052.
58. WERZ O. KLEMM J, RÅDMARK O, SAMUELSSON B: p38 MAP kinase mediates stress-induced leukotriene synthesis in a human B-lymphocyte cell line. J. Leuk. Biol. (2001) 70:830-838.
59. LEPLEY RA, MUSKARDIN DT, FITZPATRICK FA: Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. J. Biol. Chem. (1996) 271:6179-6184.
60. LUO M, JONES SM, PHARE SM et al.: Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J. Biol. Chem. (2004) 279:41512-41520.
61. 2 in allergic response and parturition. Nature (1997) 390:618-622.
62. FORD-HUTCHINSON AW, GRESSER M, YOUNG RN: 5-Lipoxygenase. Annu. Rev. Biochem. (1994) 63:383-417.
63. MCMILLAN RM, WALKER ERH: Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol. Sci. (1992) 13:323-330.
64. TATESON JE, RANDALL RW, REYNOLDS CH et al.: Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br. J. Pharmacol. (1988) 94:528-539
65. CARTER GW, YOUNG PR, ALBERT DH et al.: 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. (1991) 256:929-937.
66. BELL RL, LANNI C, MALO PE et al.: Preclinical and clinical activity of zileuton and A-78773. Ann. NY Acad. Sci. (1993) 696:205-215.
67. DRAZEN JM: Asthma therapy with agents preventing leukotriene synthesis or action. Proc. Assoc. Am. Physicians (1999) 111:547-559.
68. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J. Rheumatol. (1992) 19:1537-1541.
69. BROOKS CDW, STEWART AO, BASHA A et al.: R-(+)-N-[3-[5-(4-Fluorophenyl)methyl]-2-thienyl] -1-methyl-2-propynyl]-N-hydroxyurea (ABT-761), a second generation 5-lipoxygenase inhibitor. J. Med. Chem. (1995) 38:4768-4775.
70. LEHNIGK B, RABE KF, DENT G et al.: Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur. Respir. J. (1998) 11:617-623.
71. BIRD, BRUNEAU P, CRAWLEY GC et al.: (Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity. J. Med. Chem. (1991) 34:2176-2186.
72. CRAWLEY GC, DOWELL RI, EDWARDS PN et al.: Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J. Med. Chem. (1992) 35:2600-2609.
73. DUCHARME Y, BRIDEAU C, DUBE D et al.: Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids. J. Med Chem. (1994) 37:512-518.
74. HAMEL P, RIENDEAU D, BRIDEAU C et al.: Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010. J. Med. Chem. (1997) 40:2866-2875
75. WERZ O, SZELLAS D, HENSELER M et al.: Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol. Pharmacol. (1998) 54:445-451.
76. FISCHER L, SZELLAS D, RADMARK O et al.: Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. (2003) 17:949-951.
77. LAUFER S, TRIES S, AUGUSTIN J et al.: Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforsch (1994) 44:629-636.
78. SAFAYHI H, MACK T, SABIERAJ J et al.: Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther. (1992) 261:1143-1146
79. ALBERT D, ZUNDORF I, DINGERMANN T et al.: Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem. Pharmacol. (2002) 64:1767-75.
80. MANO T, STEVENS RW, ANDO K et al.: Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase. Bioorg. Med. Chem. (2003) 11:3879-3887.
81. MANO T, OKUMURA Y, SAKAKIBARA M et al.: 4-[5-Fluoro-3-[4-(2-methyl-1H-imidazol-1-yl) benzyloxy]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide, an orally active inhibitor of 5-lipoxygenase with improved pharmacokinetic and toxicology characteristics. J. Med. Chem. (2004) 47:720-725.
82. FISCHERL, STEINHILBER D, WERZ O: Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br. J. Pharmacol. (2004) 142:861-868
83. HWANG SB: Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. J. Lipid Mediat. (1990) 2:123-158.
84. CAI X, SCANNELL RT, YAEGER D et al.: (+ /-)-Trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy) -5-(N-methyl-N-hydroxyureidyl)methylphenyl]-5- (3,4,5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. J. Med. Chem. (1998) 41:1970-1979.
85. QIAN C, HWANG SB, LIBERTINE-GARAHAN L et al.: Anti-inflammatory activities of LDP-392, a dual PAI: receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol. Res. (2001) 44:213-220.
86. GARCEAU D, FORD-HUTCHINSON AW, CHARLESON S: 5-Lipoxygenase inhibitors and allergic conjunctivitis reactions in the guinea-pig. Eur. J. Pharmacol. (1987) 143:1-7.
87. ROQUET A, DAHLEN B, KUMLIN M et al.: Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am. J. Respir. Crit. Care Med. (1997) 155:1856-1863.
88. WILSON AM, ORR LC, SIMS EJ et al.: Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am. J. Respir. Crit. Care Med. (2000) 162:1297-301
89. ISHII K, YAKUO I, SETO Y et al.: Antiallergic activity and mode of action of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide in experimental animals. Arzneimittelforschung (1993) 43:148-154.
90. SHIZAWA T, MAEDA K, ABE K et al.: Effects of TMK688, a novel anti-allergic drug, on allergic nasal obstruction and exudative responses in sensitized guinea pigs. Naunyn Schmiedebergs Arch. Pharmacol. (1997) 356:815-819.
91. 1 receptor antagonist activity. Bioorg. Med. Chem. Lett. (2004) 14:2265-2268
92. LEWIS TA, BAYLESS L, DIPESA AJ et al.: 5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds. Bioorg. Med. Chem. Lett. (2005) 15:1083-1085.
93. 1 receptor antagonist /5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur. J. Pharmacol. (2005) 506:265-271.
94. ZOUBOULIS CH C, SABOROWSKI A, BOSCHNAKOW A: Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology (2005) 210:36-38.
95. ZOUBOULIS CC, NESTORIS S, ADLER YD et al.: A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch. Dermatol. (2003) 139:668-670.
96. WHITNEY LW, LUDWIN SK, MCFARLAND HF et al.: Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Neuroimmunol. (2001) 121:40-48.
97. NEU I, MALLINGER J, WILDFEUER A et al.: Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients. Acta Neurol. Scand. (1992) 86:586-587.
98. HAYNES J JR, BALIGA BS, OBIAKO B et al.: Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. Blood (2004) 103:3945-3950.